Thalassemia Market by Therapeutic Classes (Iron Chelating Drugs [Exjade/Jadenu]), Pipeline (Gene Therapy [LentiGlobin]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global thalassemia market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising awareness about available treatment options, increasing demand of improved curative gene therapies, and huge population.
 

Thalassemia is a rare inherited blood disorder which causes abnormal production of hemoglobin is an infected person. Patients having insufficient hemoglobin suffers from thalassemia. The production of hemoglobin is accountable for the destruction of red blood cells which leads to anemia. Thalassemia is caused due to mutation or abnormality in one or more genes responsible for generation of hemoglobin. As stated by the National Center on Birth Defects and Developmental Disabilities, in the U.S. around 1,000 people are affected by thalassemia.

A person becomes a carrier of thalassemia when that person is affected by one infected gene from parents. As thalassemia is a hereditary disorder therefore one parent is a bearer of thalassemia. The danger of giving birth to infant who is affected by thalassemia is high as both the parents are bearers. Alpha thalassemia and beta thalassemia are two types of thalassemia. Currently, there are only two treatment options, which are Blood transfusion therapy and iron chelation therapy. This generates multiple opportunities for the universal curative treatment of thalassemia development in the market.

Based on the Thalassemia International Federation, around 7.2 % people globally suffers from diseases and conditions related to hemoglobin, out of which approximately 69.8% had sickle cell anemia. Globally, around 2% people are suffering from different types of thalassemia which is around 4.5 in every 10,000 infants around the world. Greece, South Asian countries such as Maldives and India, some parts of Italy, major Mediterranean islands such as Cyprus, coastal regions of Turkey are dominated by the disease.

Market Trends, Drivers, Restraints, and Opportunities

• Growing prevalence of thalassemia and rise in pipeline drugs in thalassemia are major factors that are projected to boost the market growth over the forecast period.
• Rising number of bone marrow transplant and blood transfusion therapy, increase in number of spleen surgeries, and growth in the number of blood transfusion and chelation therapy treatments are anticipated to drive the market growth.
• cost-effectiveness and easy accessibility of treatment, and increased investment on research and development activities are estimated to push the growth of the market in the coming years.
• Increasing novel therapies development, rising awareness about thalassemia among people, and rising population are expected to fuel the market growth over the forecast period.
• Huge number of transfusion dependent patients and rising healthcare spending are anticipated to boost the market growth in the coming years.
• High cost of treatment and increasing coupled risks are projected to hamper the growth of the market during the forecast period.
• Increasing expenditure of research & development and administrating adjustments are expected to impede the expansion of the market.

Scope of the Report

The report on the global Thalassemia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Iron chelating drugs segment is projected to hold a major market share
On the basis of therapeutic classes, the thalassemia market is divided into iron chelating drugs. The iron chelating drugs segment is expected to account for a key share of the market during the forecast period. The iron chelating drugs is further subdivided into Exjade/Jadenu (deferasirox). Medicines for this disease largely includes excess iron due to blood transfusions, indicaxanthin which is an antioxidant, fetal hemoglobin elevating drugs, and vitamin supplements for the hemoglobin breakdown prevention.
The thalassemia therapeutics market is projected to show rising commercial opportunity when drugs which are under phase II/III clinical pipeline receive approval of regulatory bodies. Growing awareness about treatment modalities among people and launch od novel treatments are projected to boost the growth of the segment. Moreover, huge youth population in developing countries such as India and Pakistan are expected to fuel demand of thalassemia drugs and treatments over the forecast period.

Gene therapy segment is expected to expand at a rapid pace
Based on pipeline, the market is segmented into gene therapy. The gene therapy segment is anticipated to expand at a rapid pace during the forecast period. The gene therapy is further subdivided into LentiGlobin. Presently, for the treatment of thalassemia there are around 15 pipeline products which are under clinical trials out of which many products are based on gene therapy and targeted on giving cure for the condition. The gene therapy is potential for changing the thalassemia treatment landscape among substantial challenges of clinical development and regulatory uncertainties.

North America is expected to dominate the market
On the basis of regions, the thalassemia market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure. Moreover, launch of gene therapy for treatment, beneficial government initiatives and increase in number of research partnerships are expected to drive the regional market growth. The U.S. holds major market share owing to increasing awareness about condition among people, growing number of populations with thalassemia carrier gene, and rise in birth rates because of variation of genes within the population.
 

Segments

Segments Covered in the Report
The global thalassemia market has been segmented on the basis of

Therapeutic Classes

• Iron Chelating Drugs
  • Exjade/Jadenu (deferasirox)

Pipeline

• Gene Therapy
  • LentiGlobin

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Bluebird bio, Inc.
• Acceleron Pharma, Inc.
• Celgene Corporation
• GlaxoSmithKline plc.
• Incyte Corporation
• Gamida Cell
• Kiadis Pharma
• La Jolla Pharmaceutical Company
• IONIS Pharmaceuticals

Competitive Landscape

Key players competing in the thalassemia market are bluebird bio, Inc.; Acceleron Pharma, Inc.; Celgene Corporation; GlaxoSmithKline plc; Incyte Corporation; Gamida Cell; Kiadis Pharma; La Jolla Pharmaceutical Company; and IONIS Pharmaceuticals. Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.